Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

  1. Martín, M.
  2. Lluch, A.
  3. Seguí, M.A.
  4. Ruiz, A.
  5. Ramos, M.
  6. Adrover, E.
  7. Rodríguez-Lescure, Á.
  8. Grosse, R.
  9. Calvo, L.
  10. Fernandez-Chacón, C.
  11. Roset, M.
  12. Antón, A.
  13. Isla, D.
  14. del Prado, P.M.
  15. Iglesias, L.
  16. Zaluski, J.
  17. Arcusa, A.
  18. López-Vega, J.M.
  19. Muñoz, M.
  20. Mel, J.R.
Revue:
Annals of Oncology

ISSN: 0923-7534,  1569-8041

Année de publication: 2006

Volumen: 17

Número: 8

Pages: 1205-1212

Type: Article

DOI: 10.1093/ANNONC/MDL135 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus